Data / Drug companies / Naproxen and esomeprazole magnesium
Naproxen and esomeprazole magnesium: 10 companies and 21 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Naproxen and esomeprazole magnesium is listed in the FDA National Drug Code Directory by 10 companies, with 21 products in commercial distribution. 21 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, delayed release, and the newest product started marketing on July 23, 2026.
The request: Get every company that lists naproxen and esomeprazole magnesium in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 10
- Products
- 21
- Generic (ANDA) products
- 21 (100.0%)
- Application numbers
- 3
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list naproxen and esomeprazole magnesium
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Preferred Pharmaceuticals Inc. | 4 | tablet, delayed release | Generic drugs (ANDA) | July 23, 2026 |
| Phoenix RX LLC | 3 | tablet, delayed release | Generic drugs (ANDA) | October 11, 2023 |
| Ajanta Pharma USA Inc. | 2 | tablet, delayed release | Generic drugs (ANDA) | October 6, 2022 |
| Asclemed USA, Inc. | 2 | tablet, delayed release | Generic drugs (ANDA) | February 18, 2020 |
| Bryant Ranch Prepack | 2 | tablet, delayed release | Generic drugs (ANDA) | October 11, 2023 |
| Dr. Reddy's Laboratories Limited | 2 | tablet, delayed release | Generic drugs (ANDA) | February 18, 2020 |
| Proficient Rx LP | 2 | tablet, delayed release | Generic drugs (ANDA) | October 11, 2023 |
| ScieGen Pharmaceuticals, Inc. | 2 | tablet, delayed release | Generic drugs (ANDA) | October 11, 2023 |
| Bryant Ranch Prepack | 1 | tablet, delayed release | Generic drugs (ANDA) | October 6, 2022 |
| Doc Rx | 1 | tablet, delayed release | Generic drugs (ANDA) | February 18, 2020 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, delayed release | 21 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 21 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Nonsteroidal Anti-inflammatory Drug | 21 |
| Proton Pump Inhibitor | 21 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.